Pharmacokinetics of RFT5-SMPT-dgA in 2 patients treated with 15 mg/m² IT. Patient no. 10 (▴) received 4 infusions of 7.1 mg IT and patient no. 11 (○) received 4 infusions of 5.8 mg IT. Patient no. 10 had massive tumor burden with diffuse involvement of lung, liver, and bone marrow with high levels of sCD25 (6,497 U/mL), whereas patient no. 11 showed minimal tumor mass and significant lower sCD25 levels (523 U/mL). Both patients showed no significant differences in CD25 expression of peripheral mononuclear blood cells.